Burstein HJ et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2008;26(11):1810-6. Abstract
Burstein HJ et al. Metronomic chemotherapy with and without bevacizumab for advanced breast cancer: A randomized phase II study. San Antonio Breast Cancer Symposium 2005;Abstract 4.
Dang C et al. The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer. J Clin Oncol 2008;26(8):1216-22. Abstract
Jain RK. Lessons from multidisciplinary translational trials on anti-angiogenic therapy of cancer. Nat Rev Cancer 2008;8(4):309-16. Abstract
Kerbel R. Angiogenesis: What is the target? Presentation. Breast Cancer Symposium 2008. No abstract available
Kozloff M et al. Preliminary results of a phase I study of sunitinib plus paclitaxel for first-line treatment of advanced breast cancer. Breast Cancer Symposium 2007;Abstract 163.
Mariani G et al. Sequential administration of sunitinib (SU) and docetaxel (D) in women with advanced breast cancer (ABC): An exploratory evaluation. Proc ASCO 2008;Abstract 14534.
Mayer EL et al. A pilot study of adjuvant bevacizumab and chemotherapy after neoadjuvant chemotherapy for high-risk breast cancer. Proc ASCO 2008;Abstract 519.
Rastogi P et al. Preoperative chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 2008;26(5):778-85. Abstract
Schneider BP et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 2008;26(28):4672-8. Abstract
Neil Love, MD
Breast Cancer Update:
A CME Audio Series and Activity